Research & Results

Ongoing Research

The Dattoli Cancer Center & Brachytherapy Research Institute serves as one of the world’s foremost research institutes in the treatment of prostate cancer using the combined modalities of external radiation and seed implantation. Continuing to further define the role of the Palladium-103 isotope, either as the sole modality or in conjunction with DART, is the Dattoli Team’s greatest focus. In fact, the Dattoli program of integrating modern transperineal seeding with sophisticated DART beam radiation in the treatment of prostate cancer is the largest and most longstanding of its kind in the world.

Clinical Trials

At the Dattoli Cancer Center & Brachytherapy Research Institute, our focus in the clinical studies arena is to participate in research that will have a positive impact on the quality of life and survival of our patients seeking treatment for prostate cancer.

Currently we are involved in the Comprehensive, Observational, Multicenter Prostate Adenocarcinoma Registry (COMPARE) designed to collect data on the treatment of prostate cancer patients with a rising PSA. Physicians enrolling patients to this registry treat those individuals with their standard protocols and share information regarding response to therapy and survival in what promises to become a national database which will undoubtedly lead to future research endeavors. In addition, we are conducting numerous retrospective chart analyses, including but not limited to, comparing the efficacy of Uroxatral™ and Flomax™ (both alpha-blockers used to alleviate temporary urinary symptoms) in the immediate post-implant period. In addition, a prospective Combidex trial partnered with University of Nijmegen, The Netherlands and University of California, San Francisco, is currently under way. Our goal with respect to research trials is to ask, and perhaps answer, questions that are important enough to have a direct impact on the individual patient.

Other Relevant Prostate Publications

For other relevant prostate publications please see the “Most Relevant Prostate Publications” in Dr. Dattoli’s CV.

Keep Informed

Dattoli, M., Sorace, R., Bravo, S., Bostwick, D.; ASCO Genitourinary Cancer Symposium February 2015 Poster Presentation on the Advantages of 3D Color Flow Doppler Ultrasound Guided Biopsies (3DCFPDU). ASCO-GU, 14100 February 2015

Dattoli, M: Active Surveillance: A Dark Side? Prostate Cancer Communication (PAACT) Volume 30: Number 4 – Winter 2014

Myers, C, Dattoli, M, Bravo, S: Oligometastatic Prostate Cancer. PCRI Insights, Vol 15, No 1 2012 p 14-19

Dattoli, M, America: Beware the UroRad. Choices – Prostate Cancer Communication, (PAACT). Volume 27, Number 2 – June 2011

USPIO (Feraheme): Advanced Diagnostics for Prostate Cancer Beyond the Gland

Contact Us for Your Free Consultation

WHAT OUR PATIENTS SAY ABOUT US

"With a rising PSA and Gleason 6, I chose to put my care in the hands of the Dattoli team, undergoing IMRT and brachytherapy. Two years down the road and 74 seeds later I'm back in the pilot’s seat and flying the newest birds in the fleet – the Boeing 777s. It is important – it’s imperative - to look at every option and get yourself to the very best treatment center you can find.”

“My aggressive treatment at the Dattoli Center has given me a new appreciation for life. I suffer no ill effects from the combination treatment, but I admit that I am a “changed man.” I'm a vocal advocate for prostate cancer education and screening, especially in the African-American community. Now, I rarely miss an opportunity to race a sailboat. It is a feeling of “euphoria,” one that I savor as often as possible.”

In the winter of 2019, 64-year-old Kim F. was treated for breast cancer at the Dattoli Cancer Center. “I received a real education about my tumor and how radiation works. I admit that I felt a little out of place being surrounded by so many men being treated, but I can’t imagine getting better care than this.” Kim learned that the Dattoli Cancer Center is the only center in the country offering a radiation guidance system that can aim pinpoint radiation to the tumor while sparing the nearby heart and lungs. This is especially important when treating cancer in the left breast in such close proximity to the heart.

“Half-way around the world is not too far to travel to get the best care. Five years later, I'm like new – no evidence of prostate cancer at all. With my children on their own and more time on my hands, I've completed a 750-mile pilgrimage in 2004 and am back climbing mountains. The view from the top is awesome!"

"My seeds were implanted in early 2000. Today I am happy, healthy and a grateful man. My PSA is barely detectable at 0.094, and I embrace life full-steam ahead with Bernice by my side."